BWXT

BWX Technologies (BWXT) is drawing attention from options traders due to high implied volatility on its Nov. 20, 2026 $95.00 Call, suggesting investors expect significant price movement. However, the company maintains a Zacks Rank #3 (Hold) rating, and analyst consensus estimates for the upcoming quarter have slightly declined from $1.21 to $1.19 per share over the last 60 days. The elevated implied volatility may present opportunities for premium-selling strategies rather than directional bets.

Both Centrus Energy and BWX Technologies are positioned in the growing nuclear supply chain, benefiting from surging electricity demand from AI data centers and government support for nuclear energy. Centrus has declined 54% in 2026 as it undergoes capital-intensive expansion to become a domestic producer of enriched uranium fuel for advanced reactors. BWX Technologies has fallen 22% and maintains an exclusive, stable position as the sole supplier of weapons-grade nuclear fuel for the U.S. Navy with long-term contracts.

The AI infrastructure boom continues to benefit semiconductor manufacturers and equipment suppliers. Taiwan Semiconductor Manufacturing (TSM), ASML Holding, and BWX Technologies (BWXT) have all posted strong quarterly results with positive guidance. TSM and ASML see immediate near-term benefits from AI chip demand, while BWXT benefits from increased electricity demand for AI data centers driving nuclear energy adoption.

BWX Technologies (BWXT), a supplier of nuclear fuel and components to the U.S. government, is highlighted as a stock likely to beat earnings estimates in its upcoming November 2, 2026 report. The company has demonstrated a strong earnings-beat streak with an average surprise of 13.84% over the last two quarters and currently has a positive Earnings ESP of +0.22% combined with a Zacks Rank #3 (Hold), suggesting a high probability of another earnings beat.

The article compares BWX Technologies and Rocket Lab as investment options, presenting a value versus growth dilemma. BWX offers stability through nuclear infrastructure contracts with the U.S. government and benefits from the nuclear power renaissance, trading at a reasonable 28.6x forward P/E with positive cash flow.

Rocket Lab provides high-growth potential with 38% revenue growth but currently burns cash and trades at a premium 191.8x forward P/E, with its $8 billion Iridium acquisition adding complexity. The author recommends BWX Technologies as the better 2026 investment due to its essential role in Navy contracts, reasonable valuation, and predictable profitability.

BWX Technologies, Johnson & Johnson, and UnitedHealth Group have all raised their FY26 outlooks following solid quarterly earnings. BWX Technologies saw strong commercial nuclear operations growth, J&J benefited from pharmaceutical portfolio strength, and UnitedHealth Group showed improving cost trends with a lower medical care ratio.

BWX Technologies is expanding in defense and commercial nuclear markets with $1.4 billion in naval contracts and raised 2026 guidance to $3.80 billion revenue. However, the stock trades at a 27.10X forward P/E near its five-year median, leaving limited room for execution errors. Margin pressure in commercial operations and concentration of earnings in Q4 present risks, warranting a balanced approach.

BWX Technologies shares have declined 19.8% over three months despite 18% revenue growth, a $8.4 billion backlog (up 40% YoY), and raised 2026 guidance. While the pullback improves valuation to 27.10X forward earnings, execution risks remain due to margin pressure, capital intensity in commercial operations, and Q4-heavy earnings concentration.

BWX Technologies raised its 2026 revenue outlook to $3.80 billion and adjusted EPS guidance to $4.70-$4.80 following strong Q2 results. Commercial revenues surged 71.7% to $302.5 million, driving full-year growth forecast to 45%. However, the company faces execution risks with 55% of second-half earnings concentrated in Q4 and increased capital spending pressuring Commercial margins.

The article analyzes four nuclear reactor stocks and their potential valuations by 2031. Oklo, NuScale Power, and Nano Nuclear Energy face significant execution risks with current stock prices appearing to price in substantial post-2031 growth. BWX Technologies, a more established supplier with existing revenue, carries less commercialization risk but trades at a premium valuation with limited upside room.

BWX Technologies (BWXT) is expanding its nuclear materials processing capabilities through uranium recovery, purification, and downblending activities. The company's Uranium Processing and Nuclear Services segment revenues grew significantly to $406.6 million in 2025 from $287 million in 2024, with $68.1 million attributed to higher uranium processing and downblending activity.

BWXT trades at a discount to industry peers with a forward P/S ratio of 3.23X versus 6.89X industry average, though shares have declined 23.6% over three months. The company holds a Zacks Rank #3 (Hold) with projected EPS growth of 18.45% in 2026 and 10.10% in 2027.

Three nuclear energy stocks have fallen significantly from their highs due to market headwinds. NuScale and Oklo, which develop innovative small modular reactors, have plummeted 86% and 79% respectively but lack commercial deployment and trade at extremely high valuations. BWX Technologies, a more established and profitable nuclear supplier with defense contracts, has only pulled back 40% and offers a more balanced opportunity in the resurgent nuclear market.

BWX Technologies is positioned to outperform nuclear peers Oklo and NuScale through 2030 due to its established $3.2 billion revenue base and decades of nuclear manufacturing experience. While Oklo and NuScale are still commercializing reactor technologies, BWXT generates revenue from U.S. Navy contracts, TRISO fuel production, medical isotopes, and is developing advanced reactors and microreactors. The company raised its 2026 revenue guidance to $3.8 billion with 19% growth expected.

X-Energy, a small modular reactor (SMR) developer, went public at $23 per share in April 2026 but has since dropped to $14, trading 40% below its IPO price. While the company has secured major deals with Amazon and Dow, it faces significant challenges including unproven TRISO fuel technology, regulatory hurdles with the NRC, and a premium valuation at 19x sales despite ongoing losses. The analyst recommends avoiding X-Energy in favor of more established nuclear players like BWX Technologies.

BWX Technologies is investing in workforce development with approximately 10,400 employees globally to support its expanding nuclear operations. The company offers competitive compensation, professional training, mentoring, tuition support, and leadership development programs.

BWXT's Technical Fellows program recognizes innovative employees. The stock trades at a discount to industry peers with forward P/S of 3.12X versus 7.12X industry average, and carries a Zacks Rank #3 (Hold) with projected earnings growth of 18.45% in 2026 and 10.73% in 2027.

GE Vernova received the first U.S. construction permit for its 300-MW BWRX-300 small modular reactor design from the NRC for a Tennessee Valley Authority project in Tennessee. The approval removes a major regulatory hurdle and establishes a foundation for standardized deployment across multiple projects in the U.S. and Canada. The company expects long-term revenue opportunities from fuel, maintenance, and services across the reactor lifecycle.